|
Research progress in role of SGLT2i in atherosclerotic cardiovascular disease with diabetes mellitus |
|
View Full Text View/Add Comment Download reader |
DOI:10.11915/j.issn.1671-5403.2021.04.062 |
Key words:cardiovascular diseases SGLT2 inhibitor diabetes mellitus atherosclerosis This work was supported by National Natural Science Foundation of China |
Author Name | Affiliation | E-mail | WANG Ji-Hang | Chinese PLA Medical College, Beijing 100853, China Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China Department of Cardiovascular Disease, Hainan Hospital, Chinese PLA General Hospital, Sanya 572013, Hainan Province, China | fuzhenh@126.comresearch | SHEN Ming-Zhi | Department of Cardiovascular Disease, Hainan Hospital, Chinese PLA General Hospital, Sanya 572013, Hainan Province, China | fuzhenh@126.comresearch | JIAO Yang | Chinese PLA Medical College, Beijing 100853, China Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China | fuzhenh@126.comresearch | FU Zhen-Hong | Department of Cardiology, First Medical Center, Chinese PLA General Hospital, Beijing 100853, China National Center for Clinical Medicine of Geriatric Diseases, Beijing 100853, China | fuzhenh@126.comresearch |
|
Hits: 502 |
Download times: 468 |
Abstract: |
Diabetes is a global epidemic, and poor blood glucose control has been one of the primary causes of death for patients with cardiovascular diseases. Sodium-glucose cotransporter-2 inhibitors (SGLT2i), a novel hypoglycemic agent, has attracted extensive attention due to their prominent protective action on cardiovascular system in addition to the hypoglycemic effect demonstrated in experimental and clinical studies. Previous large randomized controlled trials for SGLT2i (EMPA-RED, CANVAS, DELCARE TIMI-58) confirmed that SGLT2i, either as primary prevention or as secondary prevention, could significantly reduce the risk of cardiovascular deaths, non-fatal myocardial infarction and non-fatal stroke in patients with coronary artery disease and diabetes mellitus. However, there have been limited findings on the actions of SGLT2i, particularly their direct effects, in atherosclerotic cardiovascular disease (ASCVD). This review summarizes the research progress in the role of SGLT2i in ASCVD with diabetes, in an effort to provide more evidence for the clinical treatment of these patients. |
Close |
|
|
|